| Literature DB >> 35453267 |
Naveed Ahmed1,2, Hira Khalid3, Mariam Mushtaq3, Sakeenabi Basha4, Ali A Rabaan5,6,7, Mohammed Garout8, Muhammad A Halwani9, Abbas Al Mutair10,11,12, Saad Alhumaid13, Zainab Al Alawi14, Chan Yean Yean1.
Abstract
The high rates of bacterial infections affect the economy worldwide by contributing to the increase in morbidity and treatment costs. The present cross-sectional study was carried out to evaluate the prevalence of bacterial infection in urinary tract infection (UTI) patients and to evaluate the antimicrobial resistance rate (AMR) in a Tertiary Care Hospital in Lahore, Pakistan. The study was conducted for the period of one year from January 2020 to December 2020. A total of 1899 different clinical samples were collected and examined for bacterial cultures using standard procedures. Samples were inoculated on different culture media to isolate bacterial isolates and for identification and susceptibility testing. A total of 1107/1899 clinical samples were positive for Staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa), Escherichia coli (E. coli) and other bacterial isolates. Methicillin-resistant S. aureus (MRSA) prevalence was 16.93% from these positive cases. MRSA strains were found to be highly resistant to amikacin, clindamycin, fusidic acid, gentamicin and tobramycin, while highest sensitivity was noted against vancomycin (100%) and linezolid (100%). MRSA and high rates of multidrug resistance (MDR) pose a serious therapeutic burden to critically ill patients. A systematic and concerted effort is essential to rapidly identify high-risk patients and to reduce the burden of AMR.Entities:
Keywords: MRSA; UTIs; XDR; antibiotic stewardship; antimicrobial resistance; virulence
Year: 2022 PMID: 35453267 PMCID: PMC9025563 DOI: 10.3390/antibiotics11040516
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
List of collected samples and the prevalence of different bacterial infections.
| Organisms | Urine | Foley Tip | Cystoscopy Urine | Nephrostomy Urine | Total Positive |
|---|---|---|---|---|---|
|
| 607 | 16 | 26 | 32 | 681 |
|
| 95 | 08 | 15 | 24 | 142 |
|
| 24 | 01 | 04 | 12 | 41 |
|
| 04 | - | - | 03 | 07 |
|
| 11 | 03 | 01 | 04 | 19 |
|
| 03 | - | 01 | 02 | 06 |
| 05 | - | - | 01 | 06 | |
|
| 152 | 07 | 06 | 18 | 183 |
|
| 01 | - | 01 | 02 | 04 |
|
| 13 | 01 | 01 | 03 | 18 |
| Total organism | 915 | 36 | 55 | 101 | 1107 |
| Total no. of samples | 1534 | 94 | 104 | 167 | 1899 |
Antibiotic resistance pattern of E. coli and P. aeruginosa.
| Antibiotics | Concentration (µg) | ||||
|---|---|---|---|---|---|
| S ( | R ( | S ( | R ( | ||
| Ampicillin (AMP) | 10 | 46 | 635 (93.24) | NT | NT |
| Amp-clavulanic acid (AMC) | 20 | 76 | 605 (88.83) | NT | NT |
| Amikacin (AK) | 30 | 598 | 83 (12.18) | 126 | 16 (11.26) |
| Aztreonam (AZM) | 30 | NT | NT | 24 | 118 (83.09) |
| Ceftriaxone (3G) (CRO) | 30 | 131 | 550 (80.76) | NT | NT |
| Ceftazidime (CAZ) | 30 | NT | NT | 107 | 35 (24.64) |
| Cefuroxime (2G) (CFM) | 30 | 104 | 577 (84.72) | NT | NT |
| Cefixime (3G) (CXM) | 5 | 104 | 577 (84.72) | NT | NT |
| Ciprofloxacin (CIP) | 5 | 91 | 590 (86.63) | NT | NT |
| Co-trimoxazole (SXT) | 23.75 | 138 | 543 (79.73) | NT | NT |
| Gentamicin (CN) | 10 | 601 | 80 (11.74) | 116 | 26 (18.30) |
| Fosfomycin (FOS) | 200 | 609 | 72 (10.57) | NT | NT |
| Imipenem (IMP) | 10 | 654 | 27 (3.96) | 104 | 38 (26.76) |
| Meropenem (MEM) | 10 | 654 | 27 (3.96) | 84 | 58 (40.84) |
| Nalidixic acid (NAL) | 30 | 36 | 645 (94.71) | NT | NT |
| Nitrofurantoin (F) | 300 | 598 | 83 (12.18) | NT | NT |
| Piperacillin-tazobactam (TZP) | 10 | 571 | 110 (16.15) | 129 | 13 (9.15) |
| Tetracycline (TE) | 30 | 117 | 564 (82.81) | NT | NT |
| Tobramycin (TOB) | 10 | 634 | 47 (6.90) | 98 | 44 (30.98) |
| Colistin (CT) | 10 | NT | NT | 137 | 05 (3.52) |
| Polymyxin (PB) | 300 units | NT | NT | 136 | 06 (4.22) |
| Cefepime (FEP) | 30 | NT | NT | 73 | 69 (48.59) |
NT: not tested. S: sensitive. R: resistant.
Antibiotic resistance pattern of S. aureus (n = 183).
| Antibiotics | Concentration (µg) | Antibiotic Susceptibility Testing | Resistance % | |
|---|---|---|---|---|
| Sensitive | Resistant | |||
| Amikacin (AK) | 30 | 118 | 65 | 35.51 |
| Cefoxitin (FOX) | 30 | 152 | 31 | 16.93 |
| Ciprofloxacin (CIP) | 5 | 76 | 107 | 58.46 |
| Co-trimoxazole (SXT) | 23.75 | 89 | 94 | 51.36 |
| Gentamicin (CN) | 10 | 107 | 76 | 41.53 |
| Linezolid (LZD) | 30 | 183 | 00 | 00 |
| Clindamycin (DA) | 2 | 136 | 47 | 25.68 |
| Erythromycin (E) | 15 | 89 | 94 | 51.36 |
| Nitrofurantoin (F) | 300 | 179 | 04 | 2.18 |
| Penicillin (P) | 10 units | 07 | 176 | 96.17 |
| Tetracycline (TE) | 30 | 29 | 154 | 84.15 |
| Teicoplanin (TEC) | 30 | 183 | 00 | 00 |
| Tobramycin (TOB) | 10 | 111 | 72 | 39.34 |
| Vancomycin (VA) | MIC | 183 | 00 | 00 |
MIC: minimum inhibitory concentration.
Primer sequences of genes of E. coli, P. aeruginosa and MRSA.
| Organisms | Genes | Sequences of Primer (5′-3′) | Annealing | Reference |
|---|---|---|---|---|
|
|
| F-TGCAGAACGGATAAGCCGTGG | 60 °C for 1 min | [ |
| R-GCAGTCACCTGCCCTCCGGTA | ||||
|
| F-ACATTCACGGCAAGCCTCAG | 58 °C for 1 min | [ | |
| R-AGCGAGTTCCTGGTGAAAGC | ||||
|
|
| F-GAAGGCGTTTATGTTCATAC | 55 °C for 1 min | [ |
| R-GTATGTTTCAAGAGTGATGC | ||||
|
| F-CTGAAGGTGTACGGAAACAC | 54 °C for 1 min | [ | |
| R-GTTCGGCCACCTCGAATTG | ||||
|
|
| F-GCGATTGATGGTGATACGGTT | 50 °C for 30 s | [ |
| R-AGCCAAGCCTTGACGAACTAAAG | ||||
|
| F-GATCGCAACGTTCAATTTAATTT | 50 °C for 30 s | [ | |
| R-GCTTTGGTCTTTCTGCATTCCT |